Marina joined Nouscom in 2016 as the Chief Operating Officer from Versant Ventures where she was an Operating Principal.
Prior to Versant, Marina was at Novartis Pharma in Basel in various senior development and commercial roles. As the Global Commercial Head, Near Patient Testing Unit, she developed the global strategy for a point of care diagnostics platform. Her experience in molecular diagnostics includes In Vitro Diagnostics development; she led development of a Companion Diagnostics for RYDAPT™, the first approved AML drug in over 3 decades. Marina managed the Global Neurodegeneration portfolio for Novartis driving her Brands to a blockbuster status.
Marina spent 5 years with McKinsey & Company in Chicago, working with Healthcare Fortune 500 companies in areas of marketing, strategy and pricing.
Marina received her PhD in Chemistry from Yale University. She authored peer reviewed publications covering HIV/AIDS research.